S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
My No. 1 dividend stock for a LIFETIME of income. (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
My No. 1 dividend stock for a LIFETIME of income. (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
My No. 1 dividend stock for a LIFETIME of income. (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
My No. 1 dividend stock for a LIFETIME of income. (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Price Target & Analyst Ratings

$8.37
+0.01 (+0.12%)
(As of 03/6/2023)
Add
Compare
Today's Range
$8.35
$8.55
50-Day Range
$6.90
$8.40
52-Week Range
$2.66
$8.55
Volume
10.73 million shs
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Concert Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$21.00
150.90% Upside
High Prediction$25.00
Average Prediction$21.00
Low Prediction$17.00
TypeCurrent
3/26/22 to 3/26/23
1 Month Ago
2/24/22 to 2/24/23
3 Months Ago
12/26/21 to 12/26/22
1 Year Ago
3/26/21 to 3/26/22
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.00$19.67$19.67$12.00
Predicted Upside150.90% Upside307.81% Upside256.71% Upside264.37% Upside
Get Concert Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

CNCE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNCE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Concert Pharmaceuticals Stock vs. The Competition

TypeConcert PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.64
2.47
Consensus RatingHoldBuyHold
Predicted Upside150.90% Upside2,007.33% Upside23.66% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/20/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
1/19/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/19/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform
1/19/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
3/4/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00+518.18%
10/5/2021Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Difei Yang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$13.00 ➝ $9.00+186.62%
12/16/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+95.47%
(Data available from 3/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CNCE Price Target - Frequently Asked Questions

What is Concert Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Concert Pharmaceuticals stock is Hold based on the current 4 hold ratings for CNCE. The average twelve-month price prediction for Concert Pharmaceuticals is $21.00 with a high price target of $25.00 and a low price target of $17.00. Learn more on CNCE's analyst rating history.

Do Wall Street analysts like Concert Pharmaceuticals more than its competitors?

Analysts like Concert Pharmaceuticals less than other Medical companies. The consensus rating for Concert Pharmaceuticals is Hold while the average consensus rating for medical companies is Buy. Learn more on how CNCE compares to other companies.

Is Concert Pharmaceuticals being downgraded by Wall Street analysts?

Over the previous 90 days, Concert Pharmaceuticals's stock had 3 downgrades by analysts.

Does Concert Pharmaceuticals's stock price have much upside?

According to analysts, Concert Pharmaceuticals's stock has a predicted upside of 204.57% based on their 12-month price targets.

What analysts cover Concert Pharmaceuticals?

Concert Pharmaceuticals has been rated by Jefferies Financial Group, JMP Securities, Jonestrading, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CNCE) was last updated on 3/26/2023 by MarketBeat.com Staff